Application of combination of NK cells and TFPI in prevention and treatment of nasopharyngeal carcinoma
A technology of NK cells and nasopharyngeal carcinoma, which is applied in the field of medicine, can solve the problems of NK cells with low anti-tumor ability, achieve high market value, improve curative effect, and promote the effect of inhibition
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0027] 1. Experimental materials
[0028] 1. Tissue factor pathway inhibitor (TFPI): commercially available;
[0029] 2. Natural killer cells (NK cells): NK cells from human umbilical cord blood;
[0030] 3. Cancer cells: EBV-positive nasopharyngeal carcinoma cells (HK1-EBV);
[0031] 4. Immunodeficient NCG mice: commercially available.
[0032] 2. Experimental group
[0033] 1. Blank control group: EBV-positive nasopharyngeal carcinoma cells were not treated with any drugs.
[0034] 2. TFPI group: EBV-positive nasopharyngeal carcinoma cells were treated with TFPI.
[0035] 3. NK cell group: use NK cells to treat EBV-positive nasopharyngeal carcinoma cells.
[0036] 4. NK cells+TFPI group: NK cells and TFPI were used to treat EBV-positive nasopharyngeal carcinoma cells at the same time.
[0037] 3. Subcutaneous tumor formation experiment in immunodeficient NCG mice
[0038] 1. Divide 5×10 6 EBV-positive nasopharyngeal carcinoma cells (HK1-EBV) were implanted subcutaneousl
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap